A Phase II Study of the Efficacy of Perioperative Pembrolizumab Therapy in Patients with Oligometastatic Renal Cell Carcinoma and Resectable Metastases.
Principal Investigator
Dott.ssa Alessandra Mosca
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
To evaluate the efficacy of pembrolizumab in delaying tumor progression in patients with oligometastatic metastatic clear-cell renal cell carcinoma who are candidates for radical surgery and/or curative radiation therapy to the metastases.
metastatic renal cell carcinoma, mRCC
Pathologies
Kidney cancer (renal cancer)
Medication
Pembrolizumab
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria may participate in this study.
1st line (previous surgery for primary tumor).
Back to search page